Glucotrack, INC 8-K filings

Glucotrack, Inc. files an amendment to its 8-K to update pro forma financials reflecting its merger with Lokahi Therapeutics and a 1-for-15 reverse stock split.

Glucotrack, Inc. has amended its common stock purchase warrants to comply with Nasdaq listing requirements, adjusting floor prices and anti-dilution provisions.

Glucotrack, Inc. announced the pricing of a public offering of common stock and pre-funded warrants, raising approximately $3.1 million.

Glucotrack, Inc. (via Lkahi Therapeutics) provided a strategic update detailing progress on its LT-100 osteoarthritis program, expansion of its AI platform, and future monetization strategies.

Glucotrack, Inc. announced the immediate resignation of director Paul V. Goode, citing potential conflicts of interest related to ongoing merger agreement discussions.

Glucotrack, Inc. announces stockholder approval for significant share issuances related to prior financing agreements, impacting warrant exercises.

Glucotrack, Inc. has entered into agreements for convertible notes totaling approximately $11.5 million, involving new cash and rollover of existing debt, with a 22% original issue discount.

Glucotrack, Inc. has entered into a settlement agreement to resolve disputes over a $10.9 million debt, agreeing to an initial payment and a convertible promissory note.

Glucotrack, Inc. announced a 1-for-15 reverse stock split, effective August 28, 2026, to adjust its outstanding common stock.

Glucotrack, Inc. is implementing a 1-for-15 reverse stock split, effective August 31, 2026, to comply with Nasdaq's minimum bid price requirement.

Glucotrack, Inc. held its annual meeting, with stockholders approving a reverse stock split, executive compensation, and a warrant inducement, while also electing directors and ratifying the appointment of its auditor.

Glucotrack, Inc. has amended its Common Stock Purchase Agreement with White Lion Capital, LLC, adjusting terms related to commitment shares and potential future payments.

Glucotrack, Inc. announced definitive agreements for approximately $5.5 million in financing, comprising a $2.0 million equity round and a $3.5 million convertible debt follow-on investment.

Glucotrack's subsidiary, Lkahi Therapeutics, is moving forward with a simplified administration strategy for its LT-100 drug, aiming for a single injection instead of up to 15.

Glucotrack, Inc. files an amendment to its 8-K report to update details on an Exchange Agreement and a newly partitioned promissory note.

Glucotrack, Inc. has entered into an Exchange Agreement to partition a promissory note and allow for its conversion into company stock.

Glucotrack, Inc. has completed a strategic business combination with Lokahi Therapeutics, Inc., establishing a new public platform focused on healthcare asset development.

Glucotrack, Inc. has received notice of potential delisting from Nasdaq due to failure to meet minimum bid price and stockholders' equity requirements.

Glucotrack, Inc. reported Q1 2026 financial results and the submission of its Investigational Device Exemption (IDE) to the FDA for its implantable CBGM technology.

Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the FDA for a U.S. clinical study of its novel implantable continuous blood glucose monitoring technology.

Glucotrack, Inc. has entered into an agreement to exchange a $988,000 promissory note for 1,300,000 shares of common stock.

Glucotrack, Inc. has entered into an Exchange Agreement to convert a portion of its outstanding promissory note into company stock, impacting its capital structure.

Glucotrack, Inc. announced its full year 2025 financial and operating results, highlighting progress in its implantable continuous blood glucose monitoring technology and a strengthened balance sheet.

Glucotrack, Inc. announced plans to submit an Investigational Device Exemption to the FDA in Q2 2026 for its novel continuous blood glucose monitoring technology, following successful international clinical trials.

Glucotrack, Inc. stockholders approved proposals for significant stock issuances to Sixth Borough Capital Fund and warrant holders, and ratified its independent auditor at a special meeting.

Glucotrack, Inc. announced the U.S. Patent and Trademark Office has issued three patents for its proprietary continuous blood glucose monitoring (CBGM) platform, strengthening its intellectual property.

Glucotrack, Inc. announced a $4.0 million private placement of pre-funded and common warrants with a single institutional investor to fund general corporate purposes and working capital.

Glucotrack, Inc. announced the issuance of an investor presentation on December 29, 2025, providing updated information to stakeholders.

Glucotrack reports Q3 2025 financial results, highlighting strengthened balance sheet, progress on its CBGM technology, and an anticipated FDA IDE submission in Spring 2026.

Glucotrack, Inc.'s special meeting of stockholders was permanently adjourned due to a persistent lack of quorum, preventing any business from being conducted.